Single-cell imaging of the heat-shock response in colon cancer cells suggests that magnitude and length rather than time of onset determines resistance to apoptosis.
INTRODUCTION
Proteasome inhibitors have recently been proposed as novel chemotherapeutic agents, with bortezomib currently approved for the treatment of multiple myeloma (Chen et al., 2011) . Although it is suggested that cancer cells have an increased sensitivity to proteasome inhibitors compared with non-transformed cells, clinical studies to date have demonstrated limited success in solid tumours (Driscoll et al., 2011) . Indeed, the utilisation of bortezomib is further complicated by the fact it has dose-limiting effects including the induction of peripheral neuropathies (Aghajanian et al., 2002; Bruna et al., 2010) . As such there is a need to enhance the therapeutic efficacy of proteasome inhibitors for their use as chemotherapeutic agents not only for the treatment of multiple myeloma but also for other malignancies.
Since the emergence of the proteasome as a target for anticancer treatment, much research has focused on establishing the mechanisms mediating the cytotoxicity of proteasome inhibitors. The ability of proteasome inhibitors to induce cytotoxicity is mediated by their ability to induce apoptosis in the cancer cells. This has, in part, been attributed to the stabilisation of proapoptotic factors such as p53 (Lopes et al., 1997; MacLaren et al., 2001 ) and the induction and/or accumulation of BH3 proteins such as Puma (Concannon et al., 2007; Ding et al., 2007) and Noxa (Fernández et al., 2005; Qin et al., 2005) . However, as with many therapies, not all tumour types respond equally to these compounds. Several years ago it was first noted that proteasome inhibitors are potent inducers of the cytoprotective heat-shock proteins (Hsps) (Bush et al., 1997) . Indeed, previous studies including microarray studies in our laboratory have identified members of the Hsp70 family of proteins as the most potently induced genes following proteasome inhibition (Concannon et al., 2007) . Increased expression of Hsp70 has been noted in a variety of cancers (Mosser and Morimoto, 2004) , where it is involved in survival and inhibition of its expression or function has been demonstrated to induce spontaneous cell death in tumours (Leu et al., 2009; Nylandsted et al., 2000) as well as enhancing sensitivity to chemotherapeutic agents (Ray et al., 2004; Schmitt et al., 2003) . The cytoprotection afforded by increased Hsp70 expression has been attributed to its ability to bind a number of molecules including Apaf-1 (Beere et al., 2000) , Bax (Gotoh et al., 2004) and AIF (Ravagnan et al., 2001 ) and also by modulating signalling pathways such as indirectly suppressing the phosphorylation of Jun N-terminal kinase (JNK) (Meriin et al., 1999) .
There is increasing evidence that tumour resistance and relapse phenomena is directly related to the ability of certain tumour cells to escape cell death through inhibition of apoptotic signalling pathways (Indran et al., 2011) . Therefore the future successful long-term utilisation of proteasome inhibitors as chemotherapeutic agents might be limited unless strategies to bypass the survival pathways activated by them can be utilised simultaneously. Furthermore, owing to genetic differences between cells within a tumour, not all cells will respond similarly to treatment. Indeed, such heterogeneity in tumour responses might be a function of variation in the protein expression profiles of individual cells and/ or exposure of different regions of the tumour to different metabolic and environmental factors. Currently, it is unclear as to whether cytoprotective responses to proteasome inhibitors are induced in all tumour cells equally; show different activation kinetics in sensitive versus resistant cells; or interact functionally with cell death pathways. In order to begin to address these important questions, we created a colon cancer cell line that expressed the enhanced green fluorescent protein (EGFP) under the control of the HSP70 promoter, and performed time-lapse single-cell imaging studies to analyse the kinetics of HSP70 promoter activity in relation to the onset of cell death following treatment with the proteasome inhibitor epoxomicin (Meng et al., 1999) .
RESULTS
Generation of a EGFP-based reporter system for monitoring HSP70 promoter activation
In order to investigate the activation of the HSP70 promoter at the single-cell level we created a vector whereby the expression of EGFP was driven by a fragment of the human HSP70 promoter (Fig. 1A) . Using this construct we created a HCT116 cell line stably expressing this vector (HCT116-Hsp70-EGFP). In initial experiments we compared the magnitude of HSP70 mRNA induction in this cell line with that in the parental HCT116 cells following a mild preconditioning heat shock at 43˚C for 1 hour and subsequent recovery at 37˚C for up to 8 hours. As demonstrated in Fig. 1B , there was no significant difference in the levels of Hsp70 induction between the wild-type (WT) HCT116 cells and the HCT116-Hsp70-EGFP cells, suggesting that the construct did not interfere with the induction of the endogenous HSP70 mRNA. Next, we investigated whether we could detect increased EGFP expression within the HCT116-Hsp70-EGFP cells following a heat-shock stimulus in the presence and absence of triptolide, an inhibitor of HSF1 (Fig. 1C) (Westerheide et al., 2006) . For these experiments, the cells were imaged prior to heat shocking at 43˚C for 1 hour and the same cells were imaged following recovery at 37˚C for 4 and Fig. 1 . Characterisation of a fluorescent reporter system for analysis of HSP70 promoter activation. (A) Schematic of the EGFP reporter construct used in the study. The expression of EGFP is driven by a ,350 bp fragment of the human HSP70 promoter. (B) WT HCT116 and HCT116-Hsp70 cells were heat shocked at 4360.5˚C for 1 hour and allowed to recover for up to 8 hours at 37˚C. Control cells were maintained at 37˚C throughout the experiment. Expression of HSP70 mRNA normalised to b-actin was examined by real-time qPCR and expressed relative to control cells. Data are means 6 s.e.m. from n53 independent samples; n.s. not significant. (C) Schematic of the experimental conditions used to test the induction of EGFP in the HCT116-Hsp70 cells. (D) HCT116-Hsp70 cells were heat shocked at 4360.5˚C for 1 hour in the absence (top panels) and presence of triptolide (bottom panels) and allowed to recover at 37˚C for indicated time periods. Scale bar: 50 mm. (E,F) Real-time qPCR analysis of the induction of the endogenous HSP70 (E) and exogenous EGFP mRNA (F) revealed similar levels of expression following treatment with 50 nM epoxomicin for 8 or 16 hours. Control cultures were treated with 0.1% DMSO for 16 hours. Data are mean 6 s.e.m. from n56 cultures from two independent experiments and are expressed relative to control treated cultures. *P,0.05 compared with control-treated cultures (ANOVA post-hoc Tukey). (G) The induction of Hsp70 and EGFP proteins was assessed in epoxomicin (50 nM)-treated cells for the indicated periods or in the control (0.1% DMSO for 24 hours). Western blotting was performed using antibodies recognising Hsp70 and EGFP proteins and revealed a similar pattern of expression for both proteins. b-actin served as a loading control.
8 hours. A time-dependent increase in the number and intensity of GFP-positive cells was evident in cells that were subjected to heat shock alone (Fig. 1D, left panels) . This increased GFP expression was prevented by pre-treatment with the triptolide for 30 minutes before the heat shock (Fig. 1D, right panels) . These results demonstrated that the induction of EGFP in the HCT116-Hsp70-EGFP cells was dependent on a functional HSF1 response. After establishing a cell line that expressed EGFP under the control of the HSP70 promoter and which was inducible under conditions of heat shock, we sought to further investigate whether the expression of the ectopic EGFP gene correlated with increased expression of the endogenous HSP70 gene under conditions of proteasome inhibition. Using real-time quantitative PCR performed on the Hsp70 reporter cell line we found robust induction of HSP70 and EGFP mRNA following treatment with the highly specific inhibitor of the chymotrypsinlike activity of the 20S proteasome inhibitor epoxomicin (Meng et al., 1999) (Fig. 1E,F) . A detailed time-course analysis of Hsp70 and EGFP protein levels by western blotting displayed similar kinetics during a 24 hour treatment period (Fig. 1G ). These data suggest that the cell line generated was a suitable tool to investigate Hsp70 activation at the single-cell level.
Single-cell imaging of Hsp70 reporter activity
In order to gain insights into the kinetics of Hsp70 activation at the single-cell level, we monitored HSP70 promoter activity using time-lapse epifluorescence microscopy. Control experiments were performed initially to demonstrate that activation of the HSP70 promoter did not occur from the imaging procedure. As shown in Fig. 2A ,B single-cell monitoring of EGFP expression revealed that it was not significantly induced over the 24 hour time period in HCT116 cells expressing EGFP under the control of HSP70 and imaged at 5 minute intervals ( Fig. 2A,B) . Next, we investigated single-cell responses of HCT116-Hsp70-EGFP cells to epoxomicin treatment. Cells were treated with 50 nM epoxomicin and monitored for a 24 hour time period. As demonstrated in Fig. 2C -E, the cellular responses to epoxomicin treatment were quite heterogeneous in terms of basal EGFP expression as well as in the magnitude and onset of increases in EGFP ( Fig. 2C-E) . From the generated single-cell traces, it was evident there is a steady baseline of EGFP expression both prior to and immediately after epoxomicin treatment. From here on, the cellular responses became quite heterogeneous. The EGFP expression in many cells started to increase until a steady state was reached. However, the time of onset of this increase in EGFP expression, as well as the speed of the observed increase, differed from cell to cell. Furthermore, there remained some cells in the population that were not seen to modulate their EGFP expression above baseline levels. To ensure that any changes in the expression of EGFP levels did not occur because of the effects of proteasome inhibition on the stability of the EGFP protein or because of changes in cell morphology we performed imaging experiments in which EGFP was expressed from a CMV promoter in HCT116 parental cells. In this setting no detectable increase in the expression levels of EGFP was detected following epoxomicin treatment (supplementary material Fig. S1 ), suggesting that the increases in EGFP expression seen in the HCT116-Hsp70-EGFP cells are not the result of non-specific increases in EGFP levels. Next, to analyse these single-cell traces in detail, and to correlate traces with onset of cell death, we fitted sigmoidal curves to the previously generated singlecell traces. These traces enabled us to measure a number of key parameters including the basal EGFP expression, the time to onset of an increase in EGFP expression, the fold of the increase in EGFP and finally the time to onset of the plateau in EGFP expression reached (Fig. 3A) . We next performed the real-time imaging experiments with varying concentrations of epoxomicin (10-50 nM). Cell death was monitored over time by examining membrane blebbing. When blebbing was observed through the cell, cell death was deemed to have occurred. Cell death levels observed under these conditions were 4.461.8% in control cultures; 13.6662.36% with 10 nM epoxomicin; 50.7063.13% with 30 nM epoxomicin; and 88.6660.92% for cultures treated with 50 nM epoxomicin. The time to onset of cell death was dose dependent with cells undergoing cell death earlier at the higher concentration of epoxomicin (Fig. 3B) . Next, we dichotomised the cells on the basis of whether or not they underwent cell death within the time frame of the real-time imaging experiment (24 hours) and investigated whether the cells that underwent cell death had differences in the key parameters shown in Fig. 3A compared with cells that were resistant to epoxomicin treatment at the end of the experiment. We found that the basal expression levels did not significantly differ between those cells that underwent cell death and those that survived at any concentration of epoxomicin (Fig. 3C) . Similarly, there was no correlation with the time of onset of EGFP induction between resistant and dying populations (Fig. 3D ). By contrast, surviving cells had significantly increased levels of EGFP induction compared with their dying counterparts (Fig. 3E) . Indeed, the time to onset of the plateau of EGFP induction occurred much later in the surviving cells compared with those that underwent cell death ( Fig. 3F) .
High-content screen analysis of Hsp70 activation
Although the epifluorescence live-cell images gave valuable information as to the heterogeneity seen with the induction of Hsp70 and its role in mediating survival it was limited by the number of cells that could be analysed. With this in mind we used a Cellomics high-content screening platform that allowed us to dramatically enhance the number of cells that could be analysed and use a number of treatment conditions in each experiment. Furthermore, it allowed for analysis of all single-cell kinetics in the population and has therefore the potential to reveal the presence of rare sub-populations that could have been overlooked or missed using standard epifluorescence live-cell microscopy. Using the Cellomics platform, we analysed single-cell HSP70 promoter activation kinetics on a much higher-throughput scale and the incorporation of propidium iodide (PI) into the medium allowed us to distinguish the cells that were alive from those that underwent cell death. Similar to the previous experiments, we detected a dose-dependent increase in the fraction of cells that underwent cell death (Fig. 4A) . From our analysis, the existence of different populations of cells that underwent cell death at different time points and with variations in the level of EGFP induction became evident. Some of the cells underwent cell death at early time points, others at intermediate time points whereas others died much later in the experiments. For the purposes of clarity, those cells that died in the time period up to 520 minutes were classified as early-onset death, those that died from 520-800 minutes were classified as intermediate onset cell death, and those that died between 800 and 1100 minutes were classified as late-onset death. The median EGFP expression from the cells within these groups was plotted as a single trace for the various different concentrations of epoxomicin used ( Fig. 4B-E) . At the lowest concentration of 10 nM epoxomicin, the cells that were resistant to the treatment showed a modest increase in EGFP expression whereas the cells that underwent cell death in either the early, intermediate or late groupings showed no induction of EGFP (Fig. 4C) . At the highest concentration of epoxomicin, a clear trend of increased expression of Hsp70 correlating with survival became evident. The cells grouped into the intermediate or late-onset death demonstrated lower and less persistent levels of Hsp70 induction compared with the resistant cells. More importantly, the cells that died in the early-onset death group showed little if any EGFP induction, demonstrating that even at high stress levels, a lack of Hsp70 induction was an indicator of poor outcome (Fig. 4E) . The cells that displayed increased HSP70 reporter activity did so with dose-dependent kinetics (Fig. 4F) . Taken together, these data suggest that there is a surprisingly heterogeneous response to epoxomicin treatment in terms of Hsp70 induction, with variation from little or no induction to very strong induction within the population of cells. Furthermore, the magnitude and persistence of Hsp70 induction appeared to correlate with cell survival.
To ensure that the increased expression of EGFP was not a function of the increased survival of cells independently resistant to Hsp70 induction, we investigated the induction of EGFP following transient expression of the reporter construct in cells with and without functional expression of p53. As shown in supplementary material Fig. S2A , the HCT116 p53 2/2 cells were remarkably resistant to epoxomicin treatment compared with the WT HCT116 cells. Despite the differences in the levels of cell death induced, the levels of GFP induction in both of the cell types were similar, although the HCT116 p53 2/2 cells appeared to have a moderate difference in the number of cells that induced GFP (supplementary material Fig. S2B ), this might be due to differences in the transfection rates between the two cell lines. Indeed, analysis of the induction of Hsp70 in the two cell lines by western blotting revealed that the levels of Hsp70 expression were comparable between the cell types (supplementary material Fig. S2C ), suggesting that the expression of Hsp70 or its surrogate EGFP were not dependent on the absence of cell death. Length and magnitude of the heat-shock response rather than time of onset correlates with cell survival
We also performed an analysis of the single-cell EGFP kinetics from the Cellomics experiments as described in Fig. 3A . The analysis of a much higher number of individual cells kinetics validated our previous observations and demonstrated that neither the basal level of EGFP (Fig. 5A ) nor the onset of EGFP induction differed significantly between resistant and apoptotic cells (Fig. 5B ). By contrast, the level of the EGFP increase was significantly higher in cells that survived the epoxomicin treatment (Fig. 5C) . Furthermore, the time of maximal EGFP induction (plateau duration) was significantly longer in the surviving cells compared with those that underwent cell death at all epoxomicin concentrations investigated (Fig. 5D) . Taken together, these data suggest that the ability of cells to sufficiently activate Hsp70 expression and for a significant time period serves as a key determinant of cellular fate.
Co-treatment with a HSF1 inhibitor prevents Hsp70 induction and enhances sensitivity to cell death To further investigate the functional significance of Hsp70 induction for cell survival, we used the previously described inhibitor of HSF1 activity, triptolide (Westerheide et al., 2006) . We had previously observed that pre-treatment of HCT116-Hsp70 cells with triptolide prevented heat-shock-induced expression of the EGFP reporter (Fig. 1D ). In line with these observations, we noted that triptolide also served as a potent inhibitor of epoxomicin induced Hsp70 expression in HCT116 cells (Fig. 6A) . In order to assess the functional consequence of inhibition of Hsp70 induction, we next tested the levels of cell death induced by epoxomicin in the presence and absence of pretreatment with triptolide. As shown in Fig. 6B , pre-treatment with 10 nM triptolide resulted in a dramatic increase in the levels of cell death induced following epoxomicin treatment when analysed by the Cellomics assay. Interestingly, the sensitisation to cell death afforded by triptolide pre-treatment was most evident at later time points, which correlated with the higher levels of Hsp70 induction that were most evident 16-24 hours after epoxomicin treatment (Fig. 6A) . Treatment with triptolide alone did not significantly modulate levels of cell death during the time course of the experiment. In parallel, we investigated the fraction of cells that accumulated EGFP following epoxomicin in the same experimental paradigm. Interestingly, EGFP accumulation was only evident in epoxomicin-treated cultures. The pre-treatment with triptolide prevented the epoxomicin-mediated GFP accumulation (Fig. 6C ). In line with these findings, the plateau of GFP induction and the fold increase in GFP expression were significantly reduced in epoxomicin-treated cultures that had been pre-incubated with triptolide ( Fig. 6D,E) . In a parallel approach, we could confirm that enhancement of epoxomicin-induced cell death levels was not limited to triptolide treatment because cells transfected with siRNA to knock down Hsp70 had enhanced sensitivity to epoxomicin treatment compared with cells transfected with control siRNA (supplementary material Fig. S3 ). These data suggest that the induction of Hsp70 functionally interacts with cell death pathways during epoxomicin-induced apoptosis.
DISCUSSION
Since the observation that inhibition of the proteasome preferably induces cell death in tumour cells (Chauhan et al., 2005; Rajkumar et al., 2005; Wu et al., 2010) , much research has centred on the use of proteasome inhibitors as chemotherapeutic agents and the molecular mechanisms by which they mediate their pro-apoptotic effects. However, a potential detrimental sideeffect associated with treatment with proteasome inhibitors is their ability to in parallel induce the expression of the protective heat-shock proteins (Bush et al., 1997) . In this study, we created a novel EGFP-based system to analyse the activation of the HSP70 promoter in real time. The transactivation of the HSP70 promoter construct resulted in increased expression of EGFP in a similar manner and level to that of endogenous Hsp70. Using live-cell imaging, we analysed activation of the HSP70 promoter following proteasome inhibition in real time in relation to whether cells survived the treatment or underwent cell death. Importantly, we could demonstrate that cells resistant to the effects of proteasome inhibition had higher levels of Hsp70 induction for more prolonged periods than their counterparts that died as a result of treatment. The time of the onset of Hsp70 induction did not correlate with survival; however, a population that did not activate Hsp70 expression was seen to undergo apoptosis within an early time-frame. The effects of Hsp70 on modulating cell death were unidirectional, with inhibition of Hsp70 induction significantly enhancing levels of cell death, whereas p53-deficient cells, which did not significantly undergo cell death, displayed similar levels of Hsp70 to their wild-type counterparts.
Several studies have previously shown that Hsp70 expression has been shown to interfere with cancer cell death mediated by proteasome inhibition (Bush et al., 1997; Gabai et al., 2005; Zhou et al., 1996) . In our study, we could demonstrate that constitutive activity of HSP70 promoter expression per se was not a determinant of cellular outcome. However, acquisition of increased levels of HSP70 promoter activity, rather than the timing of this expression, was significantly associated with enhanced cell survival. Furthermore, those cells still alive at the end of treatment had acquired characteristics that can potentially render them insensitive to future treatment. Elevated expression of Hsp70 has been reported in several cancers (Chuma et al., 2003; Guzhova and Margulis, 2006; Huang et al., 1995) . Initially, it was assumed that the elevated expression of Hsp70 is the consequence of tumour transformation. However, recent studies suggest that Hsp70 also plays a key role in inhibiting cell death pathways, ultimately causing resistance in anti-cancer treatments . The construct used in our study was driven by a portion of the HSP70 promoter and contains heat-shock elements (HSEs) that function as consensus sequences for binding HSF1 (Holmgren et al., 1981; Pelham, 1982) . As such, the reporter could be viewed as a surrogate for the activation of HSF1-mediated transcription. Indeed, we could demonstrate that the HSF1 inhibitor triptolide (Westerheide et al., 2006) potently prevented the activation of our reporter. With this in mind, it is important to realise that the acquired resistance might not be entirely attributable to increased Hsp70 and might also involve other HSF1-stress-induced proteins such as Hsp90 or Hsp27.
In inducing apoptosis in cancer cells, treatment with chemotherapeutics ultimately creates an imbalance in the ratio of pro-apoptotic to anti-apoptotic proteins, leading to cell death.
Using the high-content screening and analysis platform we could demonstrate that the induction of HSP70 promoter activity was at maximum levels in cells treated with 30 nM epoxomicin with no significant differences in the levels of Hsp70 induction at 40 nM and 50 nM concentrations. By contrast, the levels of cell death induced did not display such a concentration-induced plateau. In fact, there was minimal cell death induced in the concentration range of 0-30 nM epoxomicin. Indeed, this is in line with previous studies that demonstrate that the use of low concentrations or reversible proteasome inhibitors can induce cytoprotection to subsequent stimuli (Bardag-Gorce et al., 2011; Chen et al., 2013; Stankova et al., 2013) . Only at higher concentrations (40-50 nM), when the maximum threshold for HSP70 promoter activity was reached, did significant increases in levels of cell death occur. With the loss of the flexibility in the HSP70 transcriptional response at these concentrations, it is very likely that the balance in the ratio of apoptotic to anti-apoptotic proteins turned more rapidly in favour of pro-apoptotic proteins at higher epoxomicin concentrations. Indeed, we could demonstrate that tipping the balance, by inhibiting HSF1-mediated transcription with triptolide, dramatically promoted cell death.
Similar to previous studies demonstrating a role for p53 in proteasomal-stress-induced cell death (Lopes et al., 1997; Mitsiades et al., 2002) , we saw a dramatic reduction in cell death levels in p53-deficient cells. Nevertheless, although p53 The mean values are shown with thick black lines. The horizontal brackets indicate significant (P,0.05) differences between the treatments, in the resistant cells, whereas # indicates the significant differences between the corresponding treatments of surviving and dying cells. n5397/727 (apoptotic/resistant), n5384/230 (apoptotic/ resistant), n51554/2293 (apoptotic/resistant), n51568/62 (apoptotic/resistant) cells for control, control triptolide pretreated, epoxomicin and epoxomicin-triptolide pre-treated conditions, respectively. participated in epoxomicin-induced cell death, no evidence of its involvement in Hsp70 activation was demonstrated. Therefore, the saturation of the induction of HSP70 promoter activity at levels above 50 nM epoxomicin did not result from induction of cell death, but were rather a de facto threshold level for Hsp70 induction. Although p53 expression did not modulate HSP70 induction, our data does not exclude a possible interplay between Hsp70 and p53. Interestingly, a previous study has demonstrated that Hsp70 and p53 interacted, suggesting a potential role for Hsp70 in the regulation of p53 conformation (Hainaut and Milner, 1992) , a mechanism that might explain our findings. However, Hsp70 is known to modulate the apoptotic cascades at various levels both upstream (Gotoh et al., 2004; Stankiewicz et al., 2005) and downstream of mitochondria (Beere et al., 2000; Jäättelä et al., 1998; Saleh et al., 2000) and thus might be independent of the regulation of p53-dependent signalling.
Recent evidence has alluded to a key role for HSF1, the master regulator of Hsp70 induction, in maintaining the growth and survival of tumours in what has been termed 'non-oncogene addiction' (Solimini et al., 2007) . Taken with the fact that proteasome inhibitors are potent activators of HSF1 and Hsp70 expression (Bush et al., 1997; Zhou et al., 1996) , the long-term consequences of treatment with proteasome inhibitors are not clear. To date, there have been several reports of cells and tumours developing resistance to the clinically used drug, bortezomib (Cheriyath et al., 2007; Politou et al., 2006) . Importantly, several of these studies have associated increased expression of heat-shock proteins with resistance to treatment (Johanson, 1992; Shringarpure et al., 2006) . The concomitant induction of stress signalling survival pathways alongside inducing toxicity is not unique to the use of proteasome inhibitors. Indeed, such effects have already been seen with the use of Hsp90 inhibitors, which have also attracted the interest of the pharmaceutical industry. Previous work has demonstrated that Hsp90 binds to HSF1 to render it inactive in its monomeric form (Zou et al., 1998) . Because of this interaction, it is not surprising that initial results with Hsp90 inhibitors have not been too promising, with increased expression of other Hsps, notably Hsp70 and Hsp27 (Erlichman, 2009; McCollum et al., 2006; Nowakowski et al., 2006; Powers et al., 2008) , induced when Hsp90 is inhibited from interacting with its client proteins. As such, the use of inhibitors of Hsp90 in cancer therapy could be enhanced by co-treatment with siRNA targeting Hsp70 (Guo et al., 2005) or indeed by simultaneous inactivation of HSF1 using compounds such as triptolide, which we used in this study. Similar approaches in terms of the utilisation of proteasome inhibitors as chemotherapeutic agents might enhance their efficacy and limit the acquisition of resistance to these important treatment options, as demonstrated in this study.
A distinct advantage of our HSP70 promoter reporter system is that it allows for the analysis of HSP70 promoter activity in living cells on a single-cell level. Because of this, it is also amenable to the analysis of a variety of other cellular parameters in parallel. In this manner, it could become a useful tool for the identification of inhibitors of Hsp70 expression or HSF1, whereas simultaneously allowing the monitoring of other key cellular parameters such as mitochondrial membrane potential, plasma membrane integrity and cellular morphology. Furthermore, as demonstrated in our study, this system is amenable to analysis using high-content screening platforms or 3D-culture systems. Given that HSF1 is becoming increasingly recognised as a key factor in mediating the growth and survival of tumours (Calderwood, 2012; Dai et al., 2007; Heimberger et al., 2013; Mendillo et al., 2012) , approaches such as this could be useful for identifying and characterising new inhibitors of HSF1.
MATERIALS AND METHODS
Cell culture, plasmid construction and transfection HCT116 colon carcinoma cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 mg/ml penicillin, 2 mM glutamine and 100 mg/ml streptomycin. The cells were cultured at 37˚C in a humidified atmosphere of 5% CO 2 . To generate the plasmid expressing EGFP under the control of the HSP70 promoter, a fragment of 362 bp of the HSP70-1 (HSPA1A) gene was PCR amplified from genomic data and cloned into the pGL3-neo-tk-Luc vector. This resultant vector was modified to replace the luciferase gene with the EGFP gene, resulting in a plasmid that expressed EGFP driven by the HSP70 promoter and expressed the neomycin resistance gene for the generation of stable clones. For transfection, cells were seeded in six-well plates for 24 hours before transfection using Metafectene (Biontex, Martinsried, Germany) as per the manufacturer's instructions. Stably expressing clones were selected in G418 (500 mg/ml) for 2-3 weeks. Isolation of single cell clones was achieved by serial dilution in 96-well plates until wells containing a single cell were achieved. These single-cell clones were subsequently expanded in the presence of G418.
Heat-shock treatment
Cells were seeded into T25 flasks and sealed using Parafilm. Flasks were then submerged in a circulating water bath at 4260.5˚C for 1 hour. Following heat shock, the medium was exchanged and the flasks were replaced in normal culture conditions and allowed to recover for the indicated times.
Western blotting
Following treatment, cells were harvested and resuspended in lysis buffer [62.5 mM Tris-HCl, pH 6.8, 10% (v/v) glycerine, 2% (w/v) SDS, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin and 5 mg/ml aprotinin] for 15 minutes. Following centrifugation, the protein content was assayed using the micro-BCA kit (Thermo Fisher Scientific, Northumberland, UK) and 20 mg of protein separated on 10% SDS-PAGE gels. Following transfer to nitrocellulose, the resultant blots were probed with either mouse monoclonal antibodies to Hsp70 (StressGen Biotechnology, Victoria, Canada) or b-actin (Sigma, Dublin, Ireland) or a rabbit polyclonal antibody against EGFP (Merck Biosciences, Darmstadt, Germany). Secondary antibodies conjugated to HRP were purchased from Thermo Fisher Scientific and detected using a FujiFilm Las 3000 imager (Fuji, Sheffield, UK).
Real-time qPCR
Total RNA was extracted using RNeasy mini kit (Qiagen) as per the manufacturer's protocol. Complementary cDNA was generated from 2 mg of total RNA using SuperScript II reverse transcriptase (Invitrogen, Paisley, UK) primed with random hexamers. Real-time quantitative PCR was performed using SYBR Green Mastermix and gene specific primers, with a 15 minute preincubation cycle at 95˚C followed by 40 cycles of amplification, where each cycle is characterised by three steps: 15 seconds at 94˚C, 25 seconds at 59˚C and 25 seconds at 72˚C. The generation of specific PCR products was confirmed by melting curve analysis and gel electrophoresis. The data were analysed using the Lightcycler Software 4.0 with all samples normalised to b-actin.
Epifluorescence microscopy
Cells were seeded at a density of 0.2610 5 on 12 mm glass-bottom dishes (Willco BV, Amsterdam, The Netherlands) in 200 ml of medium for at least 24 hours prior to experimentation. Medium was then exchanged with RPMI 1640 medium (Sigma-Aldrich) supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml) and 10% fetal calf serum, buffered with N-2-hydroxyl piperazine-N9-2-ethane sulfonic acid (HEPES, 10 mM; pH 7.4) and covered with mineral oil. The dish was then placed in a heated (37˚C) incubation chamber that was mounted on the microscope stage (Axiovert 200 M inverted microscope) and allowed to reach equilibrium for at least 40 minutes before imaging. The microscope was equipped with a 636 1.4 NA (numerical aperture) objective (Carl Zeiss, Germany) with EGFP excitation at 472630 nm, a beam splitter at 495 nm and the emission collected at 520635 nm. Images were acquired every 5 minutes and recorded using a cooled EM CCD camera (Hamamatsu C9100-02, Japan). Cells were first imaged for 1 hour to constitute the base line and then treated directly on stage with the drug of interest (i.e. epoxomicin 50 nM). Experiments were run at least for 24 hours following the experiment. The imaging set-up was controlled by AxioVision software, release 4.4 (Carl Zeiss, Germany).
High-content screen imaging and data processing Cells were imaged in 96-well plates using a Cellomics ArrayScan VTi instrument (Thermofisher, Surrey, UK) equipped with a 106 PlanApo objective lens (NA 0.45), a 120 W Hg arc illumination source (EXFO) and a monochrome CCD camera (Hamamatsu Orca AG). Each experimental condition corresponded to at least three wells in the plate. A time series of images (nine fields of view) were registered from each well at 10 minute intervals, with 102461024 pixel resolution (645 nm pixel size). The fluorescence of Hsp70-EGFP (whole cell) was excited using 470-490 nm light and collected in 500-550 band, whereas the fluorescence of propidium iodide (PI, nuclei of dead cells) was excited using 555-580 nm and collected in the 595-675 band. Transmitted light was registered using a halogen lamp illumination. No crosstalk between the EGFP and PI channels was detectable in these experimental conditions. Processing of the image data was implemented in Matlab 2007a (MathWorks Inc.) with Delft Image Processing (DIP) toolbox version 2.1. The images of the cell (EGFP) and nuclear (PI) fluorescence were preprocessed using grey level opening (70 pixel window) followed by Gaussian filtering (35 pixel window) for background subtraction. The corrected images (EGFP and PI) were summed and the intensity threshold was calculated using an Otsu algorithm with a minimum value corresponding to the 99th percentile of the background intensity distribution. This threshold value was used to segment the total mask corresponding to cells which were positive for PI, EGFP or both these labels. Local maxima (corresponding to cell centres or nuclei) were isolated from the corrected images using watershedding (spurious maxima were suppressed with H-maxima transform). The cells (or nuclei) were segmented with object growing using the local maxima as seeds and the total mask to limit the growth. Clusters of objects were split using binary opening. Average intensities of PI and EGFP intensities (without background correction) were calculated over the segmented cell (or nuclear) masks. The objects were tracked using the linear assignment problem approach, implemented in u-track toolbox (Jaqaman et al., 2008) . Object positions (centroids) and average fluorescence intensities (EGFP) were used to compute similarity between objects in different frames. Track splitting/merging was allowed and the window for closing gaps in tracks was set to three frames and the tracks that did not contain at least three consecutive frames were discarded from further processing. The time course of EGFP and PI intensities were stored and minimum background threshold (99th percentile of intensity) was used as Hsp70-EGFP estimator for the cells that were not detected (and tracked) from the onset of experiment. The tracks were modelled using piecewise linear fit implemented in the SLM toolbox (D'Errico, John. SLM-Shape Language Modeling, MATLAB Central File Exchange. Retrieved September 1, 2010). The fit was carried out with 5 knots (first and last were fixed in time), where knot 2 corresponded to the onset of Hsp70-EGFP fluorescence increase and knot 3 corresponded to the plateau, respectively. Total area occupied by cells was calculated at the end of experiment from the transmitted light image and converted to cell number with control where all cells were PI-positive, serving as a standard to calculate average cell area.
Statistical analysis
For the analysis of mRNA and protein expression data are represented as mean 6 s.e.m. Differences between treatments were tested by ANOVA post-hoc Tukey using SPSS version 19 (IBM, NY). For the real-time imaging measurements differences between groups were tested by Mann-Whitney Utest using Sigma Plot version 11 (Systat Software, London, UK). Differences were considered to be significant at P,0.05.
